Skip to content Carb-X
Carb-X
Boston University
Mobile Menu Toggle navigation
  • Sign Up
  • Contact
  • Twitter
  • LinkedIn
Carb-X
Boston University
Boston University
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • CARB-X Connect
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • About CARB-X
    • Overview
    • Global Threat
    • Our Strategy
    • Stewardship and Access
    • Management & Staff
    • Joint Oversight Board
    • Advisory Board
    • Careers
    • Annual Reports
    • Boston University
  • Portfolio
    • Portfolio Product Developers
    • Portfolio-Pipeline
    • CARB-X Graduates
    • Spotlight on Science
    • Portfolio Acceleration Tools
  • Partners
    • Funding Partners
    • Global Accelerator Network
  • Apply
    • Funding Themes
    • Omnibus Solicitation
    • Application Process
    • Entering Portfolio
    • Apply Here
    • Applicant Questions
  • Resources
    • Presentations
    • Videos
    • Publications
    • Education
    • PD Resources
    • Media Resources
  • News
    • CARB-X News
    • In the News
    • Antibiotic Resistance
  • Events
  • Contact
  • Legal

Portfolio Company

  • Portfolio
  • >
  • Gallery
Debiopharm

DEBIOPHARM INTERNATIONAL SA.  Lausanne, Switzerland
http://www.debiopharm.com

DEBIO1453
NARROW SPECTRUM FABI INHIBITOR

Direct-Acting Small Molecule Therapeutic
Debiopharm International SA, a Swiss-headquartered global biopharmaceutical company, has developed a novel class of antibiotics which inhibit bacterial fatty acid biosynthesis, an essential pathway in major pathogens including Neisseria gonorrhoeae, the causative bacterium in the sexually transmitted disease gonorrhea. N. gonorrhoeae’s resistance to antibiotics is a major global medical problem having acquired resistance to practically all classes of antibiotics (CDC). Debiopharm, in collaboration with CARB-X, will utilize their state-of-the-art Fabiotics drug discovery platform to develop novel therapeutics to combat drug-resistant gonorrhea.

Current Development Stage: Pre-clinical

CARB-X Investment: Initial investment of up to $2.6m with potential option payments up to $1.4m.

Initial CARB-X Investment Date: July 1, 2017

Carb-X

Led by Boston University

Copyright 2023

  • Contact
  • Careers
  • Site Credits
  • Legal
  • Twitter
  • LinkedIn

Copyright 2023